SUN-LB322: Glasgow Prognostic Score as a Useful Prognostic Factor after Pancreaticoduodenectomy For Pancreatic Cancer

2017 ◽  
Vol 36 ◽  
pp. S173
Author(s):  
M. Ogiku ◽  
Y. Ikematsu ◽  
T. Ogasawara
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factor ◽  
Prognostic Score ◽  
Glasgow Prognostic Score

scholarly journals The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Huan Zhang ◽  
Dianyun Ren ◽  
Xin Jin ◽  
Heshui Wu
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Value ◽  
Close Association ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Prognostic Significance ◽  
Glasgow Prognostic Score ◽  
Cochrane Library ◽  
Modified Glasgow Prognostic Score ◽  
High Level

Abstract Background Several studies were conducted to explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in pancreatic cancer, which reported contradictory results. The purpose of this meta-analysis was to summarize and further investigate the correlation between mGPS and overall survival (OS) in pancreatic cancer. Methods A systematic literature search was performed in PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2011 to June 20, 2020. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic significance of mGPS in patients with pancreatic cancer. Results A total of 222 non-repetitive studies were identified, and 20 related studies that explored the association between survival outcomes and mGPS in pancreatic cancer patients were finally enrolled in this meta-analysis. The results showed a significant correlation between high level of mGPS and poor OS (HR = 1.50, 95% CI 1.20–1.89, P < 0.0001). Similar results were observed in the subgroup analyses based on the treatment regimen and research region. Conclusions Our study suggested the close association between poor prognosis and high level of mGPS, which will be helpful for future clinical applications in patients with pancreatic cancer.

scholarly journals Significance of Glasgow prognostic scores in NSCLC patients treated with immunotherapy after platinum-based cytotoxic chemotherapy

2021 ◽  
Author(s):  
Hye Seon Kang ◽  
Ah Young Shin ◽  
Chang Dong Yeo ◽  
Sung Kyoung Kim ◽  
Chan Kwon Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Cox Regression ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Cytotoxic Chemotherapy ◽  
Poor Prognostic Factor ◽  
Line Therapy ◽  
Platinum Based Chemotherapy ◽  
Nsclc Patients

Abstract Background: The Glasgow prognostic score (GPS) reflects the host’s systemic inflammatory response and is a validated prognostic factor in lung cancer. However, little is known about the prognostic role in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy.Methods: This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020. We included patients who were diagnosed with unresectable advanced stage NSCLC or recurrent disease after pulmonary resection and had received at least one regimen of platinum-based chemotherapy before the administration of immunotherapy. The prognostic value of the GPS was assessed in patients with NSCLC treated with anti-PD1 or anti-PD-L1 (pembrolizumab, nivolumab, or atezolizumab). The GPS was calculated using C-reactive protein and albumin concentrations within one week before starting anti-PD1 or anti-PD-L1 treatment. Results: A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy after platinum-based chemotherapy were included in the study. Kaplan-Meier analysis revealed that higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) (log-rank P < 0.001) and overall survival (OS) (log-rank P < 0.001). In the Cox regression multivariate analysis, the hazard ratios for irPFS were 0.249 (95% confidence interval [CI]: 0.084 – 0.739, P = 0.012) for PD-L1 expression ≥ 50% and 9.73 (95% CI: 2.931 – 32.298, P < 0.001) for a GPS of 2 relative to a GPS of 0. Older age (P = 0.033), lower PD-L1 expression (P = 0.036), and higher GPS values (P = 0.007) were independently associated with shorter OS.Conclusions: Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy after platinum-based chemotherapy.

Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma

2012 ◽  
Vol 18 (5) ◽  
pp. 829-838 ◽  
Author(s):  
Kei Horino ◽  
Toru Beppu ◽  
Hideyuki Kuroki ◽  
Kosuke Mima ◽  
Hirohisa Okabe ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Prognostic Score ◽  
Glasgow Prognostic Score

Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer

2016 ◽  
Vol 29 (2) ◽  
pp. 146-151 ◽  
Author(s):  
Yasunori Otowa ◽  
Tetsu Nakamura ◽  
Gosuke Takiguchi ◽  
Ayako Tomono ◽  
Masashi Yamamoto ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factor ◽  
Neoadjuvant Chemotherapy ◽  
Squamous Cell ◽  
Prognostic Score ◽  
Clinical Stage ◽  
Glasgow Prognostic Score ◽  
Serum Levels ◽  
Stage Ii ◽  
Modified Glasgow Prognostic Score

Summary The inflammation-based modified Glasgow prognostic score (mGPS) has been shown to be a prognostic factor for esophageal cancer, but its changes in relation to neoadjuvant chemotherapy (NAC) have never been discussed. The purpose of this study was to evaluate the potential prognostic role of mGPS with regard to NAC. mGPS was evaluated on the basis of admission blood samples taken before chemotherapy and before surgery. Patients with elevated C-reactive protein (CRP) serum levels (&gt;10 mg/L) and hypoalbuminemia (&lt;35 g/L) were allocated a score of 2, patients with elevated CRP serum levels without hypoalbuminemia were allocated a score of 1, and patients with normal CRP serum levels with or without hypoalbuminemia were allocated a score of 0. A total of 100 patients with clinical stage II/III squamous cell esophageal cancer, who underwent NAC and esophagectomy between January 2007 and August 2012, were investigated. From the multivariate analysis, the grade of response to chemotherapy and post-NAC mGPS level was found to be independent prognostic factors. The overall survival rate was significantly higher in the conserved mGPS group than in the worse mGPS group (P = 0.030). Changes in mGPS during chemotherapy affected the prognosis of patients, and post-NAC mGPS is an independent prognostic factor in patients with clinical stage II/III thoracic esophageal squamous cell cancer.

The systemic inflammation-based Glasgow Prognostic Score as a prognostic factor in patients with acute heart failure

2015 ◽  
Vol 16 (6) ◽  
pp. 409-415 ◽  
Author(s):  
Shigeto Namiuchi ◽  
Tadashi Sugie ◽  
Kenya Saji ◽  
Toru Takii ◽  
Akira Suda ◽  
...  
Keyword(s):  
Heart Failure ◽  
Prognostic Factor ◽  
Acute Heart Failure ◽  
Systemic Inflammation ◽  
Prognostic Score ◽  
Glasgow Prognostic Score

Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer

Pancreas ◽  
2016 ◽  
Vol 45 (2) ◽  
pp. 211-217 ◽  
Author(s):  
Hiroshi Imaoka ◽  
Nobumasa Mizuno ◽  
Kazuo Hara ◽  
Susumu Hijioka ◽  
Masahiro Tajika ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Modified Glasgow Prognostic Score
Sign in / Sign up

Export Citation Format

Share Document